Literature DB >> 16820795

Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction.

R Nørregaard1, B L Jensen, S O Topcu, S S Nielsen, S Walter, J C Djurhuus, J Frøkiaer.   

Abstract

Prostanoids exert physiological effects on ureteral contractility that may lead to pressure changes and pain during obstruction. In the present study, we examined whether (1) obstruction changes the expression of the two cyclooxygenase (COX) isoforms, COX-1 and COX-2 in human and rat ureters and (2) administration of a selective COX-2 inhibitor influences the pelvic pressure change after experimental ureteral obstruction. Rats were subjected to bilateral ureter obstruction. Ureters were removed and dissected into a proximal dilated and distal non-dilated segment. RNA and protein were extracted and analyzed for cyclooxygenase expression by quantitative polymerase chain reaction and Western blotting. Human ureter samples were obtained from patients undergoing radical nephrectomy. Rat and human ureteral samples were processed for immunohistochemistry. COX-1, but not COX-2 mRNA, was readily detected in the normal rat ureter. COX-2 mRNA and protein expression was increased in the proximal dilated ureter compared to distal non-dilated ureter. This increased COX-2 expression was associated with increased urinary prostaglandin E2 (PGE2) excretion after release of obstruction. Immunohistochemistry showed increased COX-2 labeling in surface epithelium and smooth muscle layers in both rat and human obstructed ureters compared to control ureters. Furthermore, contractile PGE2-EP1 and thromboxane TP receptors were expressed in ureteral smooth muscle. Systemic treatment with the COX-2 selective inhibitor parecoxib (5 mg/kg/day) attenuated the pelvic pressure increase during obstruction. In summary, COX-2 expression is significantly increased in the ureteral wall in response to obstruction in the rat and human ureter and COX-2 activity contributes to increased pelvic pressure after obstruction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820795     DOI: 10.1038/sj.ki.5001616

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

Review 1.  Medical expulsive therapy for distal ureteral stones.

Authors:  Vassilios Tzortzis; Charalampos Mamoulakis; Jorge Rioja; Stavros Gravas; Martin C Michel; Jean J M C H de la Rosette
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Increased cyclooxygenase-2 expression and prostaglandin E2 production in pressurized renal medullary interstitial cells.

Authors:  Inge Carlsen; Kaitlin E Donohue; Anja M Jensen; Angela L Selzer; Jie Chen; Dix P Poppas; Diane Felsen; Jørgen Frøkiær; Rikke Nørregaard
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-07-07       Impact factor: 3.619

3.  The general practitioner and nephrolithiasis.

Authors:  Emanuele Croppi; Federica Cioppi; Corrado Vitale
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

4.  Nicotine augments glomerular injury in a rat model of acute nephritis.

Authors:  Edgar A Jaimes; Run-Xia Tian; Mahesh S Joshi; Leopoldo Raij
Journal:  Am J Nephrol       Date:  2008-10-10       Impact factor: 3.754

Review 5.  Nicotine signaling and progression of chronic kidney disease in smokers.

Authors:  Gaurav Jain; Edgar A Jaimes
Journal:  Biochem Pharmacol       Date:  2013-07-26       Impact factor: 5.858

6.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

7.  Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo.

Authors:  V Chaignat; H Danuser; M H Stoffel; S Z'brun; U E Studer; M Mevissen
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

8.  Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice.

Authors:  Chuanxu Yang; Line Nilsson; Muhammad Umar Cheema; Yan Wang; Jørgen Frøkiær; Shan Gao; Jørgen Kjems; Rikke Nørregaard
Journal:  Theranostics       Date:  2015-01-01       Impact factor: 11.556

9.  Ureteral Access Sheath Influence on the Ureteral Wall Evaluated by Cyclooxygenase-2 and Tumor Necrosis Factor-α in a Porcine Model.

Authors:  Søren Kissow Lildal; Rikke Nørregaard; Kim Hovgaard Andreassen; Frederikke Eichner Christiansen; Helene Jung; Malene Roland Pedersen; Palle Jörn Sloth Osther
Journal:  J Endourol       Date:  2017-01-24       Impact factor: 2.942

10.  Identification of prostaglandin receptors in human ureters.

Authors:  Matthias Oll; Claudia Baumann; Turang E Behbahani; Alexander von Ruecker; Stefan C Müller; Jörg Ellinger
Journal:  BMC Urol       Date:  2012-12-10       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.